NASDAQ$CDNA
CareDx Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported a revenue growth of 77% for the second quarter of 2021.
CareDx reported a strong second quarter in 2021, with a 77% increase in revenue compared to the same period last year. The company's total revenue reached $74.2 million, driven by growth in testing services and product revenue. They increased full year revenue guidance to $280 million to $290 million.
- Total revenue reached $74.2 million, a 77% increase year-over-year.
- Approximately 37,400 AlloSure and AlloMap patient results were provided, including 6,600 AlloSure Heart patient results.
- Over 65 U.S.-based transplant centers have adopted an AlloSure Kidney testing protocol.
- TX Connect manages over 29,000 transplant referrals to over 50 transplant centers from more than 800 dialysis centers and community nephrology practices.
Headline financials
Revenue & EPS history
CareDx · Revenue · Quarterly
$74.2M
Revenue by segment
CareDx · $74.2M total across 3 segments · Q2 2021
- Testing Services$64.9M+78.8%87.5%
- Product Revenue$6.9M+109.1%9.3%
- Patient and Digital Solutions$2.4M+9.1%3.2%
Forward guidance
CareDx now expects revenue to be in the range of $280 million to $290 million for the full year 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+2.4%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+7.1%
Avg return
30 days after
54%
28 / 52 earnings
Positive
+45.7%
Q1 2024
Best reaction
-24.3%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.3% | -1.6% | +3.8% | |
| Q4 2025 | -4.3% | -2.6% | -12.8% | |
| Q3 2025 | -1.8% | +5.8% | +31.4% | |
| Q1 2025 | -10.7% | -16.0% | +0.7% | |
| Q4 2024 | -0.2% | -3.8% | -14.9% | |
| Q3 2024 | +1.1% | +4.5% | +14.5% | |
| Q2 2024 | +25.7% | +26.3% | +63.8% | |
| Q1 2024 | +45.7% | +49.7% | +49.4% | |
| Q4 2023 | +12.1% | +27.3% | +11.6% | |
| Q3 2023 | +8.7% | +19.5% | +48.0% | |
| Q2 2023 | -9.3% | -17.6% | -23.5% | |
| Q1 2023 | -2.0% | -2.2% | -8.7% | |
| Q4 2022 | +16.4% | -37.9% | -37.0% | |
| Q3 2022 | -16.5% | -14.4% | -31.1% | |
| Q2 2022 | +7.7% | -4.2% | -25.2% | |
| Q1 2022 | -24.3% | -32.1% | -23.9% | |
| Q4 2021 | +10.3% | +7.2% | +6.6% | |
| Q3 2021 | -24.3% | -26.9% | -37.1% | |
| Q2 2021 | -2.5% | -4.9% | -7.4% | |
| Q1 2021 | -1.9% | -10.0% | +9.3% | |
| Q4 2020 | +2.7% | +13.2% | -20.3% | |
| Q3 2020 | -3.1% | -2.4% | +13.5% | |
| Q2 2020 | +5.2% | -0.9% | -4.3% | |
| Q1 2020 | -0.0% | +9.6% | +19.6% | |
| Q4 2019 | -5.6% | -13.2% | -11.5% | |
| Q3 2019 | -11.8% | -23.8% | -21.6% | |
| Q2 2019 | +6.8% | -15.7% | -30.4% | |
| Q1 2019 | +15.0% | +12.6% | +30.6% | |
| Q4 2018 | +7.5% | +10.2% | -10.1% | |
| Q3 2018 | -9.8% | -10.2% | -6.0% | |
| Q2 2018 | +15.3% | +14.6% | +73.1% | |
| Q1 2018 | -2.1% | -2.6% | +35.1% | |
| Q4 2017 | +24.1% | +28.5% | +51.8% | |
| Q3 2017 | +6.2% | +6.6% | +31.0% | |
| Q2 2017 | +9.2% | +26.8% | +109.9% | |
| Q1 2017 | -4.6% | -3.7% | +14.7% | |
| Q4 2016 | +5.1% | -12.2% | +13.7% | |
| Q3 2016 | +1.3% | +3.9% | -24.7% | |
| Q2 2016 | -1.0% | -2.9% | -5.3% | |
| Q1 2016 | +6.0% | — | — | |
| Q4 2015 | +7.7% | — | — | |
| Q3 2015 | +5.0% | — | — | |
| Q2 2015 | -1.6% | — | — | |
| Q1 2014 | -0.4% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q4 2012 | +0.5% | — | — | |
| Q4 2014 | -1.8% | — | — | |
| Q3 2013 | -1.0% | — | — | |
| Q3 2014 | +17.2% | — | — | |
| Q2 2013 | +0.2% | — | — | |
| Q4 2013 | +0.2% | — | — | |
| Q2 2014 | +1.9% | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro